ReviewThe Medical clinics of North America2012
The evaluation and treatment of graves ophthalmopathy.
Review in The Medical clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02316691 (B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease), which is not on this map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
B-cell Depletion Therapy With Rituximab for Thyroid Eye Disease
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Network Meta-Analysis of Different Intravenous Glucocorticoid Regimes for the Treatment of Graves' Orbitopathy.Frontiers in pharmacology · 2022Pooled it
- Tocilizumab for thyroid eye disease.The Cochrane database of systematic reviews · 2018Pooled it
- Development and evaluation of AI model with deep learning for segmentation of extraocular muscles in thyroid eye disease.PloS one · 2026Article
- Euthyroid Graves' Ophthalmopathy With Negative Antibodies (EGONA): A Comprehensive Case-Based Review.Cureus · 2025Review
- Correlation Between Changes in Extraocular Muscles and Intraocular Pressure Following Anti-Inflammatory Therapy in Active Thyroid Eye Disease.Journal of clinical medicine · 2025Article
- Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant thyroid eye disease: a prospective study.International ophthalmology · 2024Article
- Monocyte to high-density lipoprotein cholesterol ratio as a predictor of the activity of thyroid-associated ophthalmopathy.International journal of ophthalmology · 2024Article
- The Relationship between Obesity-Related Factors and Graves' Orbitopathy: A Pilot Study.Medicina (Kaunas, Lithuania) · 2022Article
- Mycophenolate Mofetil (CellCept®) in Combination With Low Dose Prednisolone in Moderate to Severe Graves' Orbitopathy.Frontiers in medicine · 2022Article
- The promising role of risk scoring system for Cushing syndrome: Time to reconsider current screening recommendations.Frontiers in endocrinology · 2022Review
- A systematic review of euthyroid Graves' disease (Review).Experimental and therapeutic medicine · 2021Review
- Article
- Unusual onset of thyroid associated orbitopathy during pregnancy: case report and review of literature.BMC endocrine disorders · 2020Review
- Evaluation of the Effect of Proptosis on Choroidal Thickness in Graves' OphthalmopathyTurkish journal of ophthalmology · 2020Article
- Visual morbidity in thyroid eye disease in Asian Indian patients.Indian journal of ophthalmology · 2020Article
- Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy.Expert opinion on investigational drugs · 2020Review
- Preliminary study of abnormalities in saccade dynamics in patients with hyperthyroidism with no pre-existing eye damage.Experimental and therapeutic medicine · 2020Article
- Recognition, Diagnosis and Treatment of Chorioretinal Folds: Current Perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- Microarray Data of Lacrimal Gland Implicates Dysregulated Protein Processing in Endoplasmic Reticulum in Graves' Ophthalmopathy.Frontiers in endocrinology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Optimum care of the patient with Graves ophthalmopathy (GO) is achieved through teamwork between the endocrinologist and ophthalmologist, with input from ancillary specialists as needed. Clinical evaluation should include determination of both the severity and the activity of the disease. It is important to assess early in the evaluation the impact of the disease on the patient's quality of life and their priorities and expectations regarding management. Once this information has been gathered, careful discussion between patient and physicians can define the management plan. This article reviews the pathophysiology, epidemiology, evaluation, and management of GO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.